Clinical trials
Glioma clinical trials
Below are recruiting glioma clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06930846Recruiting
Brain cancer cognitive training study
This study tests a home-based program called HOBSCOTCH-CA to help with memory and thinking problems after brain cancer treatment. The program uses phone and internet sessions to teach self-management skills.
Lebanon, New HampshireAges 18 years+ - NCT04111588Recruiting
PET/MRI scan to assess brain tumors and metastases
This trial tests how well a special PET/MRI scan can help doctors evaluate gliomas and brain metastases. It may help improve diagnosis and treatment planning by comparing scan results with tissue samples or surgery findings.
BergenAges 18 years+ - NCT06917885RecruitingPhase 1
CUE-102 for Recurrent Glioblastoma: A Safety Study
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Boston, MassachusettsAges 18 years+ - NCT06914479RecruitingPhase 1
Gene therapy and valacyclovir for recurrent brain tumors in young people
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Ann Arbor, MichiganAges 3–39 - NCT06910306Recruiting
DaRT alpha radiation for recurrent glioblastoma
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
Scottsdale, ArizonaAges 18–85 - NCT06831461Recruiting
Proton vs photon radiation for brain tumors
This study compares two types of radiation therapy for adults with primary brain tumors that have a good outlook (expected survival longer than 5 years). You will receive either standard photon radiation or the more targeted proton radiation, to see if one works better or causes fewer side effects.
MumbaiAges 18–70 - NCT06804655RecruitingPhase 2
Personalized drug testing for stubborn brain tumors
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
Basel, Basel-LandschaftAges 18 years+ - NCT06797661Recruiting
Brain lesion blood flow study before surgery
This study looks at how blood flow in the brain changes when there is a mass that can be removed with surgery. You would join before any treatment, which helps doctors understand the link between the brain lesion and blood vessel function.
BrusselsAges 18–90 - NCT05929495RecruitingPhase 2
Metformin added to standard treatment for newly diagnosed glioblastoma
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
MilanAges 18 years+ - NCT06753617Enrolling by invitation
Cold probe treatment for brain tumors
This trial tests a cold-based treatment (cryoablation) for certain brain tumors including gliomas, meningiomas, and metastases. It may be an option if you plan to have surgery and meet safety criteria.
Rotterdam, South HollandAges 18–80 - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06610682RecruitingEarly Phase 1
Plixorafenib for BRAF-mutated glioma
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
Baltimore, MarylandAges 18 years+ - NCT06594315Recruiting
Brain metabolism scan using deuterated glucose for glioma patients
This study uses a special sugar drink (deuterated glucose) and an MRI-like scan to measure brain metabolism. It aims to better understand how brain tumors use energy, which could help with treatment decisions in the future.
San Francisco, CaliforniaAges 18 years+ - NCT06173076Recruiting
Study of outcomes in anti-LGI1 brain inflammation
This study follows people newly diagnosed with anti-LGI1 encephalitis (a brain inflammation) to see how well they do over time. It aims to learn more about the condition and improve care.
Hangzhou, ZhejiangAges 18–100 - NCT06528691RecruitingPhase 2
Entrectinib for young children with NTRK/ROS1 brain tumors
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
Memphis, TennesseeAges Up to 3 years - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT06496971RecruitingPhase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
TaipeiAges 18–80 - NCT06465199RecruitingPhase 1/Phase 2
Eflornithine and AMXT 1501 for Advanced Childhood Cancers
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Birmingham, AlabamaAges Up to 26 years - NCT06470711Recruiting
Mapping brain electrical properties with MRI
This study uses MRI scans to map the brain's electrical properties in healthy volunteers and in people who have had surgery for a brain tumor (glioma). It aims to better understand brain function and tumor effects.
Scottsdale, ArizonaAges 18 years+ - NCT05386043Recruiting
Study brain tumor testing with MRI and extra tissue samples
This study looks at how brain tumors look on MRI and what biopsy tissue shows, using samples taken during planned surgery. It may help improve understanding of tumor biology and future treatment planning.
Indianapolis, IndianaAges 18 years+ - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
San Francisco, CaliforniaAges 18 years+
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioma?
- Yes. Clin2 currently lists 333 recruiting glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.